"Daunorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.
| Descriptor ID |
D003630
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200 D04.615.562.050.200 D09.408.051.059.200
|
| Concept/Terms |
Daunorubicin- Daunorubicin
- Daunomycin
- Rubomycin
- Dauno-Rubidomycine
- Dauno Rubidomycine
- Rubidomycin
|
Below are MeSH descriptors whose meaning is more general than "Daunorubicin".
Below are MeSH descriptors whose meaning is more specific than "Daunorubicin".
This graph shows the total number of publications written about "Daunorubicin" by people in this website by year, and whether "Daunorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Daunorubicin" by people in Profiles.
-
Stone RM, Mazzola E, Neuberg D, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. J Clin Oncol. 2015 Apr 10; 33(11):1252-7.
-
Ravi D, Muniyappa H, Das KC. Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. J Biol Chem. 2005 Dec 02; 280(48):40084-96.
-
K?hler H, Nurko S, Glickman J, Furuta GT. Acute myeloid leukemia presenting as non-neutropenic colitis in an infant. J Pediatr Gastroenterol Nutr. 2003 Nov; 37(5):631-3.
-
Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, Lee EJ, Moore JO, Powell BL, Schiffer CA. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med. 1995 Jun 22; 332(25):1671-7.
-
Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, Omura GA, Moore JO, McIntyre OR, Frei E. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 06; 331(14):896-903.
-
Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer C. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. Blood. 1991 Nov 15; 78(10):2520-6.
-
Styrt B, Klempner MS. Leukocyte uptake of daunomycin. Drug Metab Dispos. 1984 Nov-Dec; 12(6):790-1.
-
Dershwitz M, Novak RF. Lack of inhibition of glutathione reductase by anthracycline antibiotics. Biochem Pharmacol. 1981 Mar 15; 30(6):676-8.